# Epidemiological Study to Evaluate the Prevalence of Epidermal Growth Factor Receptor (EGFR) Mutation Status in Patients With Newly Diagnosed Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)

> **NCT01081496** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 1000 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01081496
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2010-08
- **Final completion:** 2011-02
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2011-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01081496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01081496, "Epidemiological Study to Evaluate the Prevalence of Epidermal Growth Factor Receptor (EGFR) Mutation Status in Patients With Newly Diagnosed Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01081496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*